015


EUROIMMUN Suspected coeliac disease


Me d i z i n i s c h e L a b o r d i a g n o s t i k a AG


Reliable diagnosis of coeliac disease: All ESPGHAN recommended tests from one source


Asymptomatic persons at risk Liver Intestine Oesophagus Anti-Endomysium IIFT Anti-tTG (IgA) + anti-DGP (IgG)


Anti-tTG >10x ULN


EmA + HLA DQ2/DQ8 Both positive


Diagnosis of coeliac disease (no biopsy required)  Gluten-free diet


Follow-up: anti-tTG, EmA  Biopsy for diagnosis


HLA DQ2/DQ8 Negative Positive No coeliac disease risk


Anti-Tissue Transglutaminase ELISA Anti-Gliadin (GAF-3X) ELISA


Accurate concentration measurement for diagnosis and diet control


Anti-Gliadin (GAF-3X) EUROPLUS Comprehensive analysis using BIOCHIP Mosaics


GAF-3X


HLA-DQ2/DQ8 EUROArray With negative results, coeliac disease is as good as excluded


ESPGHAN strategy from Husby S. et al. JPGN 2011, in print (simplifi ed). ULN: upper limit of normal; tTG: tissue transglutaminase; DGP: deamidated gliadin peptides; EmA: anti-endomysium antibodies; GAF-3X: gliadin-analogous fusion peptide as trimer – original DGP antigen based on Schwertz E. et al. Clin. Chem. 2004, 50:2370.


For further information contact Dr. J. Aldag (j.aldag@euroimmun.de; +49 451 5855 25453) EUROIMMUN AG · D-23560 Luebeck (Germany) · Seekamp 31 · Telephone +49 451 58550 · Fax 5855591 · E-mail euroimmun@euroimmun.de · www.euroimmun.com


www.lifesciencesmagazines.com


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44